Update (9:35 a.m.): Updated with Tuesday market open information.
The stock was down 12.57% to $41.75 at 9:33 a.m. on Tuesday.
Cramer is sticking with Weyerhaeuser and thinks Taser is a buy.
Some companies have powerful trends to bolster their numbers, Fed or no Fed, Cramer says.
Clovis Oncology shares were higher Wednesday after analysts with Credit Suisse boosted the stock's rating to OUTPERFORM from NEUTRAL.